As one of the only physician-founded, physician-led medical cannabis companies in the world, Vireo Health collaborates with research organizations to better understand medical cannabis, its applications, and its safety. These partnerships help to reinforce and improve the scientific underpinning of the beneficial effects of cannabis and its ability to treat a range of medical conditions.
Are you interested in partnering with Vireo to conduct a study or research project? Accredited organizations should contact: email@example.com
Vireo has an exclusive agreement to study the use of Captisol in the development and commercialization of pharmaceutical-grade cannabinoid-based products.
Vireo works with Park Nicollet to conduct randomized trials of medical cannabis in patients with newly diagnosed, stage IV cancer to assess impact on cancer-related symptoms.
Vireo is a proud part of the National Institute of Health R01 $3.8MM research grant for the first, long-term study of medical cannabis’ impact on opioid use in adults with chronic pain, in partnership with Montefiore Medical Center.
Vireo works with Northwell Health on an IRB-approved research study to examine older adults’ use of medical cannabis for chronic pain.
UNIVERSITY OF MINNESOTA
Vireo partners with the University of Minnesota on a study of Fasting, fed and chronic therapy pharmacokinetic research, which combines neuropsychological testing, DNA testing and seizure control monitoring.
THE UNIVERSITY OF IOWA
Vireo works with research at the University of Iowa to study cannabis use among older adults – how they consume, how often they consumer and what are their main motivations for consumption.
Vireo is a Founding Research Partner with mmj.org. This initiative aims to bring together diverse stakeholders in the cannabis therapy space, to advance scientific understanding of medical marijuana and its derivatives, and to provide evidence-based resources for patients and their caregivers.